47 news items
Bristol Myers Squibb Provides Update on Phase 3 CheckMate -73L Trial
BMY
10 May 24
Squibb researchers are exploring new frontiers in personalized medicine and, through innovative digital platforms, are turning data into insights
Repertoire® Immune Medicines and Bristol Myers Squibb Announce Multi-Year Strategic Collaboration to Develop Tolerizing Vaccines for Autoimmune Diseases
BMY
29 Apr 24
-leading expertise in developing and commercializing innovative immune medicines
CHMP Adopts Positive Opinion Recommending Approval of Bristol Myers Squibb's Opdivo® (nivolumab) in Combination with Cisplatin and Gemcitabine for the First-Line Treatment of Adult Patients with Unresectable or Metastatic Urothelial Carcinoma
BMY
26 Apr 24
expectations for many, Bristol Myers Squibb researchers are exploring new frontiers in personalized medicine and, through innovative digital platforms
Bristol Myers Squibb Reports First Quarter Financial Results for 2024
BMY
25 Apr 24
Initiative to Deliver ~$1.5 Billion in Cost Savings, the Majority of Which Will be Reinvested to Fund Innovation and Drive Growth
Actinium Pharmaceuticals (ATNM) Leads Biotech Innovation Amid Economic Uncertainty
ABBV
ATNM
AZN
19 Apr 24
, the biotech industry stands out as a beacon of innovation and growth potential. Actinium Pharmaceuticals, Inc
e9y7yvrd1i53qj2eg081trr75edyns6nik84h5w24n5jxkwync0u4z6g
ATNM
AZN
BMY
18 Apr 24
biotech sector continues to benefit from favorable financing conditions and a vibrant outlook for mergers and acquisitions, coupled with innovative
syzt2kvddic314tii8skjj6zzszgw0hkn ya241jglwsj1jqkksp
ATNM
AZN
BMY
17 Apr 24
of RayzeBio, highlighting the high demand and "scarcity value" of innovative companies like Actinium. Currently, ATNM is trading at less than 8
ymfw1a2y17kihqfg
BMY
6 Apr 24
Squibb is a global biopharmaceutical company whose mission is to discover, develop and deliver innovative medicines that help patients prevail over
klap3qcjzc5am o2kvvgm4pke20wm6m8j
BMY
TSVT
5 Apr 24
living with multiple myeloma by improving upon the current treatment paradigm, and we remain steadfast in our pursuit of innovation and advancing cell
0b3oynhlo qu
BMY
TSVT
5 Apr 24
pursuit of innovation and advancing cell therapy research to deliver potentially transformative therapies
5ddmul1w7ih7cprwcd
BMY
2 Apr 24
, Bristol Myers Squibb researchers are exploring new frontiers in personalized medicine and, through innovative digital platforms, are turning data
rmsrpq0jvsdbii11xyi8ccjd8damf2auqm krn
BMY
2 Apr 24
builds on its strengths to advance patient access, product innovation, culture and inclusion and diversity
hhl2dx31qp7 w07udlv6r6lyexmsj60jjou
BMY
CATX
LNTH
28 Mar 24
collaborations with world class institutions such as Stonybrook University and Mayo Clinic. We believe the innovations we are developing, supported